ANTX (AN2 Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ANTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-08 | Robin Shane Readnour | Director | Sell | — | — |
| 2026-09-04 | Sarah Joanne Williams | Principal Accounting Officer | Sell | — | — |
| 2026-09-02 | Margaret M FitzPatrick | Director | Buy | — | — |
| 2026-08-19 | Robin Shane Readnour | Director | Sell | — | — |
| 2026-08-14 | Joseph S Zakrzewski | Director | G | — | — |
| 2026-07-10 | Gilbert Lynn Marks | Director | A | — | — |
| 2026-07-10 | Joshua M Eizen | See Remarks | Sell | — | — |
| 2026-07-10 | Patricia A. Martin | Director | A | — | — |
| 2026-07-10 | Kabeer Aziz | Director | A | — | — |
| 2026-06-02 | Sarah Joanne Williams | Principal Accounting Officer | Sell | — | — |
| 2026-04-10 | Gilbert Lynn Marks | Director | A | — | — |
| 2026-04-10 | Kabeer Aziz | Director | A | — | — |
| 2026-04-10 | Patricia A. Martin | Director | A | — | — |
| 2026-03-23 | Robin Shane Readnour | Director | MIXED | — | — |
| 2026-03-23 | Stephanie Wong | Director | MIXED | — | — |
| 2026-03-23 | Melvin K Spigelman | Director | MIXED | — | — |
| 2026-03-23 | Lucy Day | Chief Financial Officer | MIXED | — | — |
| 2026-03-23 | Margaret M FitzPatrick | Director | MIXED | — | — |
| 2026-03-23 | Eric Easom | Chief Executive Officer | MIXED | — | — |
| 2026-03-23 | Sanjay Chanda | Chief Development Officer | MIXED | — | — |
| 2026-03-23 | Joseph S Zakrzewski | Director | MIXED | — | — |
| 2026-03-23 | Gilbert Lynn Marks | Director | MIXED | — | — |
| 2026-03-23 | Patricia A. Martin | Director | MIXED | — | — |
| 2026-03-23 | Kabeer Aziz | Director | MIXED | — | — |
| 2026-03-23 | Joshua M Eizen | See Remarks | MIXED | — | — |
| 2026-03-05 | Sarah Joanne Williams | Principal Accounting Officer | Sell | — | — |
| 2026-02-23 | Gilbert Lynn Marks | Director | A | — | — |
| 2026-02-23 | Robin Shane Readnour | Director | A | — | — |
| 2026-02-23 | Melvin K Spigelman | Director | A | — | — |
| 2026-02-23 | Joseph S Zakrzewski | Director | A | — | — |
| 2026-02-23 | Margaret M FitzPatrick | Director | A | — | — |
| 2026-02-23 | Sarah Joanne Williams | Principal Accounting Officer | A | — | — |
| 2026-02-23 | Patricia A. Martin | Director | A | — | — |
| 2026-02-23 | Joshua M Eizen | See Remarks | A | — | — |
| 2026-02-23 | Stephanie Wong | Director | A | — | — |
| 2026-02-23 | Kabeer Aziz | Director | A | — | — |
| 2026-02-23 | Lucy Day | Chief Financial Officer | A | — | — |
| 2026-02-23 | Eric Easom | Chief Executive Officer | A | — | — |
| 2026-02-23 | Sanjay Chanda | Chief Development Officer | A | — | — |
| 2026-01-14 | Patricia A. Martin | Director | A | — | — |
| 2026-01-14 | Kabeer Aziz | Director | A | — | — |
| 2026-01-14 | Gilbert Lynn Marks | Director | A | — | — |
| 2026-01-07 | Joshua M Eizen | See Remarks | Sell | — | — |
| 2026-01-07 | Lucy Day | Chief Financial Officer | Sell | — | — |
| 2026-01-07 | Sanjay Chanda | Chief Development Officer | Sell | — | — |
| 2026-01-07 | Stephen David Prior | Chief Strategy Officer | Sell | — | — |
| 2025-11-06 | Joshua M Eizen | See Remarks | Sell | — | — |
| 2025-11-06 | Stephen David Prior | Chief Strategy Officer | Sell | — | — |
| 2025-10-14 | Patricia A. Martin | Director | A | — | — |
| 2025-10-14 | Gilbert Lynn Marks | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 3,773,517 | — |
| — | 10%+ Owner | 3,748,087 | — |
| — | 10%+ Owner | 3,017,432 | — |
| — | 10%+ Owner | 2,475,310 | — |
| — | 10%+ Owner | 2,473,500 | — |
| — | 10%+ Owner | 2,373,500 | — |
| — | 10%+ Owner | 1,725,348 | — |
| — | Chief Executive Officer | 1,434,396 | — |
| — | Director | 567,067 | — |
| — | Director | 436,648 | — |
| — | 10%+ Owner | 415,612 | — |
| — | See Remarks | 206,554 | — |
| — | Director | 145,538 | — |
| — | Chief Development Officer | 118,823 | — |
| — | Chief Financial Officer | 118,363 | — |
| — | Director | 81,873 | — |
| — | Principal Accounting Officer | 66,311 | — |
| — | Chief Strategy Officer | 61,944 | — |
| — | Chief Medical Officer | 51,416 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ANTX quote page; the site-wide leaderboard is on the insider transactions hub.